Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.46 USD | +2.98% | +17.69% | +49.14% |
Mar. 20 | North American Morning Briefing : Markets on Hold -2- | DJ |
Mar. 19 | JPMorgan Upgrades Mersana Therapeutics to Neutral From Underweight, Price Target is $5 | MT |
Financials (USD)
Sales 2024 * | 39.05M | Sales 2025 * | 33.24M | Capitalization | 411M |
---|---|---|---|---|---|
Net income 2024 * | -83M | Net income 2025 * | -97M | EV / Sales 2024 * | 7.71 x |
Net cash position 2024 * | 110M | Net cash position 2025 * | 23.7M | EV / Sales 2025 * | 11.7 x |
P/E ratio 2024 * |
-5.07
x | P/E ratio 2025 * |
-4.65
x | Employees | 123 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.34% |
Latest transcript on Mersana Therapeutics, Inc.
1 day | +2.98% | ||
1 week | +21.40% | ||
Current month | +9.15% | ||
1 month | -18.01% | ||
3 months | +2.98% | ||
6 months | +170.31% | ||
Current year | +49.14% |
Managers | Title | Age | Since |
---|---|---|---|
Martin Huber
CEO | Chief Executive Officer | 64 | 20-04-12 |
Director of Finance/CFO | 46 | 19-07-09 | |
David Mott
CHM | Chairman | 58 | 12-07-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Kristen Hege
BRD | Director/Board Member | 60 | 16-07-31 |
David Mott
CHM | Chairman | 58 | 12-07-30 |
Anna Protopapas
BRD | Director/Board Member | 59 | 15-03-01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.05% | 0 M€ | 0.00% | - | |
0.04% | 0 M€ | 0.00% | - | |
0.03% | 237 M€ | +1.82% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 3.46 | +2.98% | 1,189,390 |
24-05-02 | 3.36 | -0.30% | 1,677,621 |
24-05-01 | 3.37 | +6.31% | 1,755,253 |
24-04-30 | 3.17 | +0.32% | 1,487,451 |
24-04-29 | 3.16 | +7.48% | 1,210,152 |
Delayed Quote Nasdaq, May 03, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+49.14% | 411M | |
-1.43% | 103B | |
+8.96% | 101B | |
+4.40% | 23.07B | |
-12.15% | 22.23B | |
-4.36% | 18.05B | |
-39.98% | 17.18B | |
-10.04% | 16.94B | |
+6.79% | 14.07B | |
+38.61% | 12.35B |
- Stock Market
- Equities
- MRSN Stock